The Science Behind Lutea

Evidence-Based PMDD Support

When we created Lutea, we didn't guess. We researched.

Every ingredient in our formula is backed by clinical studies specifically examining its effects on mood, stress response, hormone sensitivity, and the neurochemical pathways that PMDD disrupts.

These aren't random "women's health" ingredients. Each one targets specific systems that crash during PMDD episodes - from GABA and serotonin pathways to cortisol regulation and neuroinflammation.

Below you'll find the key studies we used to design Lutea's comprehensive approach to PMDD brain chemistry support.

Because when you're dealing with a condition that affects your identity, relationships, and quality of life - you deserve solutions based on real science, not marketing claims.

• 2007 Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene Huo L, et al Biol Psych

• 2020 Allopregnanolone in PMDD: evidence for dysregulated GABA-A sensitivity. Hantsoo L, Epperson CN. Neurobiol Stress.

• 2022 GABA(A) receptor modulating steroids and clinical implications. Bäckström T et al.. J Neuroendocrinol.

• 2023 Allopregnanolone-mediated GABAA-Rα4 function in amygdala and hippocampus of PMDD Sun Y, Gao M, Gao D, Chen D, Wang J. Aging

• 2023 Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of PMDD Gao et al Front Psych

• 2025 Genetic contributions to premenstrual symptoms: revisiting the role of the ESR1 gene